321 Shares in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Acquired by Brooklyn Investment Group

Brooklyn Investment Group bought a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 321 shares of the medical equipment provider’s stock, valued at approximately $35,000.

Several other institutional investors have also recently added to or reduced their stakes in ZBH. American Century Companies Inc. lifted its stake in Zimmer Biomet by 12.6% during the second quarter. American Century Companies Inc. now owns 6,463,845 shares of the medical equipment provider’s stock worth $701,521,000 after purchasing an additional 722,041 shares during the last quarter. Equity Investment Corp acquired a new position in Zimmer Biomet during the third quarter worth approximately $70,104,000. Magnetar Financial LLC increased its position in Zimmer Biomet by 58.7% during the second quarter. Magnetar Financial LLC now owns 1,310,265 shares of the medical equipment provider’s stock worth $142,203,000 after buying an additional 484,816 shares during the period. Van ECK Associates Corp increased its position in Zimmer Biomet by 12.4% during the third quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider’s stock worth $391,239,000 after buying an additional 411,163 shares during the period. Finally, Thompson Siegel & Walmsley LLC acquired a new position in Zimmer Biomet during the third quarter worth approximately $41,588,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Up 0.1 %

ZBH opened at $112.10 on Friday. The business’s fifty day moving average is $107.29 and its two-hundred day moving average is $109.45. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. The company has a market cap of $22.32 billion, a price-to-earnings ratio of 21.31, a PEG ratio of 2.06 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a one year low of $101.47 and a one year high of $133.90.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The business had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.80 billion. During the same period in the prior year, the business earned $1.65 earnings per share. The business’s revenue was up 4.1% on a year-over-year basis. Analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ZBH has been the topic of several research analyst reports. Wells Fargo & Company lifted their price target on Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Oppenheimer dropped their target price on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a report on Tuesday, October 15th. Robert W. Baird dropped their target price on Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating on the stock in a report on Thursday, August 8th. Truist Financial boosted their target price on Zimmer Biomet from $112.00 to $117.00 and gave the company a “hold” rating in a report on Friday, November 1st. Finally, Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a report on Thursday, October 31st. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $123.22.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.